Bivalent COVID-19 vaccines can be used for primary vaccination series, NACI says
Advertisement
Read this article for free:
or
Already have an account? Log in here »
To continue reading, please subscribe:
Digital Subscription
One year of digital access for only $205*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*First annual payment billed as $205.00 + GST for one year. This annual subscription will automatically renew at $233.00 + GST every 52 weeks (10% off the regular annual price of $259.35). Offer available to new and qualified returning subscribers only. Cancel any time.
To continue reading, please subscribe:
Add Free Press access to your Brandon Sun subscription for only an additional
$1 for the first 4 weeks*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*Your next Brandon Sun subscription payment will increase by $1.00 and you will be charged $17.95 plus GST for four weeks. After four weeks, your payment will increase to $24.95 plus GST every four weeks.
Read unlimited articles for free today:
or
Already have an account? Log in here »
Hey there, time traveller!
This article was published 12/06/2023 (1203 days ago), so information in it may no longer be current.
Canada’s National Advisory Committee on Immunization (NACI) says bivalent mRNA vaccines can be used as the two-dose primary series of shots against COVID-19.
That means anyone who has not yet been vaccinated against COVID-19, including infants age six months and over, can receive the bivalent formulations developed to target the Omicron variant.
The bivalent vaccines, manufactured by Moderna and by Pfizer-BioNTech, have previously been used only as booster shots for people five years of age and older.
NACI posted the new interim guidance online on Friday.
The statement says the supply of the original monovalent mRNA COVID-19 vaccines will no longer be available in Canada in the coming months.
NACI says its interim recommendation is considered “off-label” while Health Canada reviews manufacturers’ submissions for use of the bivalent vaccines for the primary vaccination series.
Canada’s Chief Public Health Officer, Dr. Theresa Tam, says NACI’s recommendation reflects evidence that the bivalent vaccines are safe and effective.
This report by The Canadian Press was first published June 12, 2023.
Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content.
